Food addiction is not currently a formal diagnosis, but at least 1 in 7 adults experience food addiction-like symptoms, loss of control, constant cravings, and eating despite harm.
Wegovy, Mounjaro and Ozempic, like medications, were developed for diabetes and obesity, and this seems to change the relationship with food. I am going to talk more about how Wegovy, Mounjaro and Ozempic-like medications act on the brain, cravings and reward pathways. Synthetic versions that are more potent and longer-lasting than the naturally occurring hormones.
What is food addiction?
Food addiction is about brain chemistry. When we eat highly palatable foods, our brain’s reward system releases dopamine in the ventral tegmental area and nucleus accumbens, the same regions involved in substance abuse.
Study shows that GLP-1 receptors are widely expressed throughout the mesolimbic reward pathway. These receptors receive direct projections from the nucleus tractus solitarius, which is a brain region crucial for processing food-related signals. When GLP-1 receptor agonists bind to these receptors, they fundamentally alter how our brain responds to food cues.
Wegovy, Mounjaro, and Ozempic-like medications don’t just act in the gut. It also acts in the brain. GLP-1 receptors are found in reward and appetite control regions like the hypothalamus, ventral tegmental area, and nucleus accumbens. These are the same regions that respond to highly palatable, high-sugar, high-fat foods. By activating these pathways, Wegovy, Mounjaro and Ozempic-like medications appear to reduce the wanting and craving signals, not just the feeling full signals.
How do Wegovy, Mounjaro and Ozempic-like medications help?
Wegovy, Mounjaro and Ozempic like medications work on two gears,
- Homeostatic gear – you get fuller sooner, and slower gastric emptying buys your brain time to register satiety.
- Hedonic gear – reactive circuits aren’t as loud, so the wanting for hyper-palatable foods decreases. Together, those changes can feel like relief from compulsive snacking, grazing, or late-night eating.
A 2024 study highlighted that GLP-1 receptor agonists dramatically improve outcomes not just for obesity, but for various addictive behaviours. The evidence shows these medications reduce both the frequency of food cravings and the intensity of reward-seeking behaviour.
Human brain imaging studies show short-term Wegovy, Mounjaro and Ozempic-like medications exposure dampens fMRI responses to food cues in reward regions such as the insula, amygdala, putamen, and orbitofrontal cortex. These are the areas that help drive cue-triggered wanting. This suggests a biological pathway for quieter cravings and less cue-reactivity.
Real-world data shows that households with at least one Wegovy, Mounjaro and Ozempic-like medication user reduced grocery spending by 5.3% within 6 months of treatment, with the largest reductions concentrated in calorie-dense, processed food categories, particularly calorie-dense, processed foods often linked to addictive-like eating.
What makes Wegovy, Mounjaro and Ozempic like medications unique is that they don’t just suppress appetite; they change how the brain processes reward signals. Research published in 2023 demonstrated that Semaglutide (Ozempic and Wegovy), a GLP-1 receptor agonist, reduces appetite while paradoxically increasing dopamine reward signalling in response to natural, healthy rewards. This suggests that Wegovy, Mounjaro and Ozempic-like medications don’t create a state of anhedonia or inability to feel pleasure. Instead, they appear to restore normal reward processing, allowing people to find satisfaction in appropriate portions of food and reducing the compulsive drive to overconsume.
Like all medications, Wegovy, Mounjaro and Ozempic-like medications have side effects, primarily gastrointestinal issues like nausea and vomiting, which typically decrease over time. However, the safety profile for approved medications like semaglutide and liraglutide is well-established through extensive clinical trials. It is important to note that these medications work best as part of a comprehensive treatment approach that includes behavioural therapy, nutritional counselling and lifestyle modifications.
Wegovy, Mounjaro and Ozempic-like medications don’t just help people lose weight; they help break the cycle of food addiction by normalising the reward pathway and reducing the compulsive drive to overeat. It is important to note that GLP-1s aren’t a cure for food addiction; if you stop them, appetite and cravings can return, and weight regain is common without ongoing support.
